Provided by Tiger Trade Technology Pte. Ltd.

Shattuck Labs, Inc.

5.57
-0.0900-1.59%
Volume:213.37K
Turnover:1.17M
Market Cap:558.52M
PE:-11.11
High:5.58
Open:5.56
Low:5.42
Close:5.66
52wk High:8.33
52wk Low:1.70
Shares:100.36M
Float Shares:67.76M
Volume Ratio:0.53
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5010
EPS(LYR):-0.7014
ROE:-39.21%
ROA:-24.43%
PB:2.65
PE(LYR):-7.93

Loading ...

Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC), Shattuck Labs (STTK) and Arcus Biosciences (RCUS)

TIPRANKS
·
Oct 05

Shattuck Labs Price Target Raised to $14.00/Share from $11.00 by Wedbush

Dow Jones
·
Oct 02

Piper Sandler Remains a Buy on Shattuck Labs (STTK)

TIPRANKS
·
Oct 02

Shattuck Labs price target raised to $19 from $17 at Needham

TIPRANKS
·
Oct 02

Shattuck Labs Inc : Needham Raises Target Price to $19 from $17

THOMSON REUTERS
·
Oct 02

Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Atricure (ATRC)

TIPRANKS
·
Oct 02

Wedbush Lifts Price Target on Shattuck Labs to $14 From $11, Keeps Outperform Rating

MT Newswires Live
·
Oct 01

Shattuck Labs (STTK) Receives a Buy from Leerink Partners

TIPRANKS
·
Oct 01

Shattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease Drug

MT Newswires Live
·
Oct 01

Shattuck Labs Names Shoba Ravichandran Senior Vice President, Clinical Development

Reuters
·
Oct 01

Shattuck Labs - Phase 2 Trial to Start in 2026; 16-Week Data Expected in H1 2028

THOMSON REUTERS
·
Oct 01

Shattuck Labs - Existing Cash Expected to Fund Operations into 2029

THOMSON REUTERS
·
Oct 01

Shattuck Labs - to Initiate Phase 2 Trial of Sl-325 in Hidradenitis Suppurativa

THOMSON REUTERS
·
Oct 01

Shattuck Labs - Ind Submission for Phase 2 Trial Expected in October 2026

THOMSON REUTERS
·
Oct 01

Shattuck Labs Announces Phase 2 Clinical Trial of Sl-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.d., as Senior Vice President, Clinical Development

THOMSON REUTERS
·
Oct 01

Pantginis Maintains Buy on Shattuck as Merck TL1A/DR3 Data De-Risk SL-325; Price Target Reiterated at $14

TIPRANKS
·
Oct 01

Shattuck Labs management to meet with Piper Sandler

TIPRANKS
·
Sep 24

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

GlobeNewswire
·
Sep 03

Raymond James Initiates Coverage on Shattuck Labs With Strong Buy Rating, $18 Price Target

MT Newswires Live
·
Aug 24

Shattuck Labs Inc : Raymond James Initiates Coverage with Strong Buy Rating; Target Price $18

THOMSON REUTERS
·
Aug 24